IL6 and myocardial infarction: The clinical trial this was based on—the ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction (ASSAIL-MI) trial—reported no significant difference in serious adverse events in the treated group compared to the placebo.